Literature DB >> 16638864

Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer.

Sambasivarao Damaraju1, David Murray, Jennifer Dufour, Diana Carandang, Sten Myrehaug, Gino Fallone, Colin Field, Russell Greiner, John Hanson, Carol E Cass, Matthew Parliament.   

Abstract

OBJECTIVE: To explore the possible relationship between single nucleotide polymorphisms (SNP) in candidate genes encoding DNA damage recognition/repair/response and steroid metabolism proteins with respect to clinical radiation toxicity in a retrospective cohort of patients previously treated with three-dimensional conformal radiotherapy (3-DCRT) for prostate cancer. EXPERIMENTAL
DESIGN: One hundred twenty-four patients with prostate cancer underwent 3-DCRT at our institution between September 1996 and December 2000. Of these, 83 consented for follow-up of blood sampling and SNP analysis. Twenty-eight patients were documented as having experienced grade >/=2 late bladder or rectal toxicity (scoring system of Radiation Therapy Oncology Group) on at least one follow-up visit. We analyzed 49 SNPs in BRCA1, BRCA2, ESR1, XRCC1, XRCC2, XRCC3, NBN, RAD51, RAD52, LIG4, ATM, BCL2, TGFB1, MSH6, ERCC2, XPF, NR3C1, CYP1A1, CYP2C9, CYP2C19, CYP3A5, CYP2D6, CYP11B2, and CYP17A1 genes using the Pyrosequencing technique.
RESULTS: Significant univariate associations with late rectal or bladder toxicity (grade >/=2) were found for XRCC3 (A>G 5' untranslated region NT 4541), LIG4 (T>C Asp(568)Asp), MLH1 (C>T, Val(219)Ile), CYP2D6*4 (G>A splicing defect), mean rectal and bladder dose, dose to 30% of rectum or bladder, and age <60 years. On Cox multivariate analysis, significant associations with toxicity were found for LIG4 (T>C, Asp(568)Asp), ERCC2 (G>A, Asp(711)Asp), CYP2D6*4 (G>A, splicing defect), mean bladder dose >60 Gy, and dose to 30% of rectal volume >75 Gy.
CONCLUSIONS: In this study, we identified SNPs in LIG4, ERCC2, and CYP2D6 genes as putative markers to predict individuals at risk for complications arising from radiation therapy in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16638864     DOI: 10.1158/1078-0432.CCR-05-2703

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

Review 1.  Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects.

Authors:  Søren M Bentzen; Matthew Parliament; Joseph O Deasy; Adam Dicker; Walter J Curran; Jacqueline P Williams; Barry S Rosenstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group.

Authors:  H H Yoon; P Catalano; M K Gibson; T C Skaar; S Philips; E A Montgomery; M J Hafez; M Powell; G Liu; A A Forastiere; A B Benson; L R Kleinberg; K M Murphy
Journal:  Cancer Chemother Pharmacol       Date:  2011-02-01       Impact factor: 3.333

3.  Unraveling biophysical interactions of radiation pneumonitis in non-small-cell lung cancer via Bayesian network analysis.

Authors:  Yi Luo; Issam El Naqa; Daniel L McShan; Dipankar Ray; Ines Lohse; Martha M Matuszak; Dawn Owen; Shruti Jolly; Theodore S Lawrence; Feng-Ming Spring Kong; Randall K Ten Haken
Journal:  Radiother Oncol       Date:  2017-02-22       Impact factor: 6.280

4.  Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.

Authors:  A Sanchez; J D Schoenfeld; P L Nguyen; M Fiorentino; D Chowdhury; M J Stampfer; H D Sesso; E Giovannucci; L A Mucci; I M Shui
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-03-01       Impact factor: 5.554

5.  Association of XRCC1 and XRCC3 gene haplotypes with the development of radiation-induced fibrosis in patients with nasopharyngeal carcinoma.

Authors:  Isabella Wai Yin Cheuk; Shea Ping Yip; Dora Lai Wan Kwong; Vincent Wing Cheung Wu
Journal:  Mol Clin Oncol       Date:  2014-04-14

Review 6.  Germline prognostic markers for urinary bladder cancer: obstacles and opportunities.

Authors:  David W Chang; Jian Gu; Xifeng Wu
Journal:  Urol Oncol       Date:  2012 Jul-Aug       Impact factor: 3.498

7.  Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.

Authors:  Marjun P Duldulao; Wendy Lee; Rebecca A Nelson; Joyce Ho; Maithao Le; Zhenbin Chen; Wenyan Li; Joseph Kim; Julio Garcia-Aguilar
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

8.  Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation dose-response in patients with non-small cell lung cancer.

Authors:  Jian-Yue Jin; Weili Wang; Randall K Ten Haken; Jie Chen; Nan Bi; Ramses Sadek; Hong Zhang; Theodore S Lawrence; Feng-Ming Spring Kong
Journal:  Radiother Oncol       Date:  2015-08-04       Impact factor: 6.280

9.  Analysis of single nucleotide polymorphisms and radiation sensitivity of the lung assessed with an objective radiologic endpoin.

Authors:  Chris R Kelsey; Isabel L Jackson; Scott Langdon; Kouros Owzar; Jessica Hubbs; Zeljko Vujaskovic; Shiva Das; Lawrence B Marks
Journal:  Clin Lung Cancer       Date:  2013-01-10       Impact factor: 4.785

Review 10.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.